ClinicalTrials.gg
RecruitingNCT04192955EVOLVEUpdated Sep 2, 2026

Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms

A Phase 3 interventional study of Acetyl Salicylate in Unruptured Cerebral Aneurysm, sponsored by University of Calgary. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by University of Calgary · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Intracranial Aneurysm with a site in Canada — 12 open to participants now, 15 under way, 1 of them phase 3. Intracranial Aneurysm · Canada.

Planned enrollment
7th of 28
440 · median 201
Started
2020
with 5 others
Phase 3
Only one
of the 38
Primary completion
2027-03
later than 5 of 14 live
Registered
27th of 38
by date

Among the 38 studies in Intracranial Aneurysm with a site in Canada, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2020, is the only one in phase 3, reaches primary completion later than 5 of the 14 other live ones, and was the 27th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

12 of the 38 studies in Intracranial Aneurysm with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Intracranial Aneurysm with a site in Canada, or all of them as a file.
02

Study summary

This trial is a is a prospective, randomized (1:1) placebo-controlled, clinical trial with blinded endpoint assessment of 440 participants with unruptured brain aneurysm planned for endovascular treatment using coiling-only approach (primary coiling or using balloon-assistance but not stenting) to test if oral acetylsalicylic acid (325 mg/ day for a total of 5 days) is superior placebo in preventing clinical and silent strokes. The primary outcome is a clinical or silent stroke at the time of discharge assessed by clinical examination and MRI brain. Participants will return to the clinic or be contacted by phone for the end of study procedures on Day 90 to collect functional outcome data.

Read the detailed description

Endovascular aneurysm treatment has become the mainstay of treatment of unruptured brain aneurysms. Since the introduction of Guglielmi detachable coils in the late 1980s, thousands of procedures are performed annually worldwide. The expanding endovascular armamentarium with the use of balloon-assisted coiling, stents (either in stent-assisted coiling or flow-diversion), and unassisted coiling-only procedures made it possible to treat aneurysms of almost all intracranial locations, shapes, and sizes.

Thromboembolic complications are potential adverse events whenever catheters are introduced into the intracranial arteries. Diagnostic and interventional neurological procedures, such as diagnostic and therapeutic cerebral angiograms may lead to ischemic strokes of varying frequency and severity. Luckily, most of the thromboembolic events do not cause a clinical stroke. Instead, tiny infarction signals are seen on Diffusion-weighted magnetic resonance imaging (DWI MRI) of the brain without neurological signs or symptoms. These are often labelled as silent (or covert) strokes. These imaging surrogates have been used to compare the safety and efficacy of various endovascular procedures and techniques. In a Canadian cohort, heparin bolus during aneurysm coiling was associated with significantly less DWI load on post-coiling MRI. This supports the notion that most of these lesions are caused by thrombi, as opposed to bubbles.

There is limited direction from available guidelines regarding the use of anticoagulation or antiplatelet agents to prevent thromboembolic complications associated with endovascular treatment of brain aneurysms. This resulted in huge variability of the protocols used for anticoagulation and antiplatelet therapies before, during and after coil embolization of brain aneurysms. Most of the current practices are extrapolated from coronary literature.

Platelet inhibition is an effective strategy to minimize the rate of thromboembolism. Antiplatelet treatment has been routinely used before coronary angioplasty to reduce the risk of thromboembolic events. The different action of ASA from that of anticoagulants gives it an additive effect to heparin alone in neuro-interventional procedures. This notion is supported by observations from multiple retrospective and prospective studies.

We will perform a prospective, randomized (1:1) placebo-controlled, clinical trial with blinded endpoint assessment of 440 participants with unruptured brain aneurysm planned for endovascular treatment using coiling-only approach (primary coiling or using balloon-assistance but not stenting) to test if oral acetylsalicylic acid (325 mg/ day for a total of 5 days: 3 days prior and two days after and including the coiling procedure day) is superior placebo in preventing clinical and silent strokes. The primary outcome is a clinical or silent stroke at the time of discharge assessed by clinical examination and MRI brain.

03

Conditions studied

  • Unruptured Cerebral Aneurysm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unruptured intracranial aneurysm suitable for coiling-only (primary coiling or balloon-assisted) as a primary treatment.
  • Functionally independent at baseline (modified Rankin scale \<3).
  • and availability of the subject for the entire study period.

Exclusion criteria

Exclusion Criteria:

  1. Planned complex aneurysm treatment including use of any device that requires post-operative antiplatelet therapy (stent-assisted coiling or flow-diverter device), or endovascular vessel sacrifice.
  2. Dissecting or mycotic brain aneurysm.
  3. Any ongoing ischemic symptoms such as , minor strokes, or stroke-in-evolution within 2 weeks before randomization.
  4. Allergy or to ASA.
  5. Unable to take study drug orally for any reason.
  6. Subjects already taking single or dual antiplatelet, warfarin, or any of the non-Vitamin K antagonist oral anticoagulants.
  7. Subjects unable to undergo MRI imaging for any reason (e.g., severe claustrophobia or presence of metals).
  8. Any other medical condition that the site investigator deems would put the subject at excessive risk by participation in the study (e.g. active bleeding, symptomatic peptic ulcer disease, liver or kidney failure, thrombocytopenia or coagulopathy) or an expected less than one year, or that would result in an inability to collect radiological outcomes and clinical outcomes at 90 days.
  9. Pregnancy or breastfeeding.
  10. Prior enrollment in EVOLVE trial for another aneurysm.
  11. Participation in another clinical trial of an drug, device or procedure if the subject received the trial drug, device or procedure in the preceding 30 days from the anticipated coiling date.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Active comparator
    Active

    Acetylsalicylic acid (ASA) will be given orally at a dose of 324 mg to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.

    Drug: Acetyl Salicylate

  • Placebo comparator
    Control

    Lactose100-mg tablets to be taken daily starting 3 days prior to the planned coiling procedure day, on the procedure day, and for one-day post-procedure.

    Drug: Acetyl Salicylate

Interventions

  • DrugAcetyl Salicylate

    Tablets

06

What researchers measure

Primary outcomes

  1. Clinical or silent stroke

    Incidence of embolic strokes (clinically or on DWI-MRI)

    Time frame: within 2-4 days of completion of the coiling procedure

Secondary outcomes

  1. Symptomatic stroke

    Clinical thromboembolic events

    Time frame: Day 90 following coiling.

  2. Death rate

    Time frame: within 90 days following coiling

  3. Peri-operative hemorrhagic complication

    intracranial hemorrhage, retroperitoneal hematoma, upper or lower gastrointestinal bleeding, or any bleeding stratified as major according to thrombolysis in myocardial infarction (TIMI) definition.

    Time frame: within 90 days following coiling

  4. Count of new DWI lesions on post-coiling MRI

    Time frame: within 2-4 days of completion of the coiling procedure

  5. Total volume of new DWI lesions on post-coiling MRI

    Time frame: within 2-4 days of completion of the coiling procedure

  6. Frequency of large (> 10 cc volume) strokes on DWI MRI

    Time frame: within 2-4 days of completion of the coiling procedure

  7. Incidence of cognitive decline on Montreal Cognitive Assessment (MoCA) from baseline to discharge.

    Time frame: within 2-4 days of completion of the coiling procedure

  8. Incidence of visible thrombus formation during the coiling procedure

    Time frame: During the procedure

07

Study locations

9 of 9 sites recruiting
  • Foothills Medical Center
    Calgary, Alberta T2N 2T9, Canada
    Recruiting
    • · Contact4039441110
    • Dr Alim Mitha, MD FRCSC · Contact
  • U of Alberta
    Edmonton, Alberta, Canada
    Recruiting
    • Cian O'Kelly, MD FRCSC · Contact
  • Dalhousie University
    Halifax, Nova Scotia, Canada
    Recruiting
    • Adrienne Weeks, MD, PhD, FRCSC · Contact
  • McMaster University
    Hamilton, Ontario, Canada
    Recruiting
    • BRIAN VAN ADEL, MD, PhD, FRCPC · Contact
  • Toronto St Michael's Hospital
    Toronto, Ontario Toronto, Canada
    Recruiting
    • Aditya Bharatha, MD FRCPC · Contact
  • Toronto Western Hospital
    Toronto, Ontario, Canada
    Recruiting
    • Ronit Agid, MD, FRCPC · Contact
  • McGill University
    Montreal, Quebec, Canada
    Recruiting
    • Maria Cortes, MD · Contact
  • University of Saskatchewan
    Saskatoon, Saskatchewan, Canada
    Recruiting
    • Michael Kelly, MD, PhD, FRCSC, FACS, FAANS · Contact
  • Centre Hospitalier Régional Universitaire de Tours
    Tours, Centre-Val de Loire, France
    Recruiting
    • Grégoire Boulouis, MD-PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Mar 2027, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2019
First posted
Dec 10, 2019
StartActual
Jul 14, 2020
Primary completionEst.
Mar 2027
CompletionEst.
Jul 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04192955
Responsible party
Sponsor
First posted
Dec 10, 2019
Start date
Jul 14, 2020
Primary completion
Mar 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Mohammed A Almekhlafi, MD MSc FRCPC
Contact
mohammed.almekhlafi1@ucalgary.ca
403-944-3458
Karla Ryckborst, RN BN CCRP
Contact
karla.ryckborst@albertahealthservices.ca
Mohammed A Almekhlafi, MD MSc FRCPC
principal investigator · University of Calgary
Mayank Goyal, MD PhD FRCPC
principal investigator · University of Calgary
Linda Andersen, PhD
study director · University of Calgary
Craig Doram, PEng
study director · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion